Emcure Expands Poviztra® Use for MASH Treatment Following CDSCO Approval

What Happened ?

Key details

Expansion of Poviztra® Indication:

• CDSCO approved the use of Poviztra® for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis (F2-F3).
• Poviztra® contains innovator rDNA-origin semaglutide.
• The product is manufactured and imported from Novo Nordisk’s European manufacturing facility.
• The approval expands Emcure’s metabolic disease portfolio beyond obesity and cardiovascular risk management. 

Clinical Evidence:

The approval is supported by findings from the global Phase III ESSENCE trial, which demonstrated:

• 63% of patients achieved resolution of steatohepatitis.
• 37% showed improvement in liver fibrosis.
• Approximately one in three patients achieved both steatohepatitis resolution and fibrosis improvement simultaneously.

These results indicate the therapy’s potential to address the underlying progression of MASH in addition to its established metabolic benefits.

Strategic Importance:

The expanded indication strengthens Emcure’s position in the rapidly growing metabolic disease segment by:

• Addressing a significant unmet medical need in liver disease.
• Expanding access to an evidence-based therapy for MASH patients.
• Enhancing Zuventus Healthcare’s gastroenterology and hepatology portfolio.
• Supporting physician awareness and earlier diagnosis of MASH.
• Reinforcing Emcure’s strategy of bringing globally validated innovative therapies to the Indian market. 

Existing Approved Uses:

Prior to this approval, Poviztra® was already approved for:

• Chronic weight management in adults with obesity.
• Overweight patients with obesity-related comorbidities.
• Obese patients with established cardiovascular disease.
• Adolescent obesity in patients aged 12 years and above.

The MASH indication further expands the product’s therapeutic applications.

Note:

• The announcement does not disclose expected sales contribution, commercial launch timelines, pricing, market size or financial impact arising from the approval.

Risk Analysis

Summary:

• The CDSCO approval strengthens Emcure’s innovative product portfolio and expands its presence in metabolic disease treatment. However, commercial success will depend on physician adoption, patient awareness and market penetration.

Key Risks:

• No revenue or sales guidance has been disclosed.
• Market adoption depends on physician prescribing patterns and patient diagnosis rates.
• Commercial execution will require increased awareness of MASH, which is often underdiagnosed.
• Competition in metabolic therapies may intensify over time.

Worst Case:

• If physician adoption or patient uptake remains slower than expected, the expanded indication may take longer to generate meaningful commercial benefits despite regulatory approval.

Risk Level: Low

Company Commentary

• Management described the approval as an important milestone for patients suffering from an often underdiagnosed liver disease.
• Emcure reaffirmed its commitment to bringing globally validated innovative therapies to Indian patients.
• The company intends to work closely with healthcare professionals to improve disease awareness, encourage early diagnosis and expand access to evidence-based treatment.
• Management stated that the new indication strengthens Emcure’s commitment to addressing complex metabolic diseases through science-led innovation while improving long-term patient outcomes.